10th Nov 2020 09:12
(Alliance News) - AstraZeneca PLC on Tuesday said data from its phase 3 trial of tezepelumab showed the drug resulted in a significant reduction in attacks in patients with severe asthma.
The FTSE 100 drug manufacturer stated the Navigator Phase 3 trial met the primary endpoint with tezepelumab added to standard of care, demonstrating a statistically significant and clinically meaningful reduction in the annualised asthma exacerbation rate over 52 weeks compared to placebo combined with standard of care.
AstraZeneca added that preliminary analyses showed no clinically meaningful differences in safety results between the tezepelumab and placebo groups.
"Due to the complex nature of severe asthma, many patients continue to face debilitating symptoms despite receiving standard of care inhaled medicines and currently approved biologics. Today's ground-breaking results show that tezepelumab has the potential to transform care for a broad population of severe asthma patients who are underserved today, including those without an eosinophilic phenotype," said Andrew Menzies-Gow, director of the lung Division at the Royal Brompton Hospital, London & principal investigator of the Navigator trial.
Shares in Astra were trading 1.5% higher at 8,429.00 pence each on Tuesday morning in London.
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca